Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   207 Trials   10745 News 


«12...4849505152535455565758...136137»
  • ||||||||||  Journal:  The best and worst of times in therapy development for myasthenia gravis. (Pubmed Central) -  Nov 3, 2022   
    The authors provide a summary of these discussions, but not a consensus opinion, and offer a series of recommendations to guide focused research in the most critical areas. We welcome ongoing discussion through comments on this publication.
  • ||||||||||  Observational data, Retrospective data, Journal:  Generalization of ocular myasthenia gravis 10 years after onset. (Pubmed Central) -  Nov 2, 2022   
    Our population's percentage of OMG generalization is in line with recent publications. Using the identified prognostic factors, the nomogram provided a score to predict the probable risk of generalization in our cohort.
  • ||||||||||  Review, Journal:  SARS-CoV-2 vaccination and new-onset myasthenia gravis: A report of 7 cases and review of the literature. (Pubmed Central) -  Nov 2, 2022   
    Here we report 7 cases of new-onset myasthenia gravis in timely association with SARS-CoV-2 vaccination, including the first paediatric case identified to date. We also reviewed the literature for other new-onset MG cases reported within 4 weeks of SARS-CoV-2 vaccination and discuss our findings in the context of altered (auto)immunity following SARS-CoV-2 vaccination and/or infection.
  • ||||||||||  pyridostigmine Bromide / Generic mfg.
    Review, Journal:  COVID-19 and myasthenia gravis: A review of neurological implications of the SARS-COV-2. (Pubmed Central) -  Oct 29, 2022   
    Risk factors identified in our study aid the management of pregnancy in MG women. Further clinical studies are warranted to indicate and rather confirm if MG in the setting of COVID-19 can pre-existent subclinically or develop as a new-onset disease.
  • ||||||||||  Retrospective data, Journal:  Robotic thymectomy for thymomas: a retrospective follow-up study in the Netherlands. (Pubmed Central) -  Oct 28, 2022   
    Robotic thymectomy was found to be safe and feasible for early stage thymomas, most advanced-stage thymomas, and thymomatous myasthenia gravis. A national guideline could contribute to the improvement of the oncologic follow-up of thymic epithelial tumors in the Netherlands.
  • ||||||||||  propranolol / Generic mfg.
    THYROID STORM PRESENTING AS NEUROMUSCULAR WEAKNESS: A DIAGNOSTIC DILEMMA () -  Oct 26, 2022 - Abstract #ATA2022ATA_531;    
    Endocrinology was consulted and she was started on thiouracils, Lugol's solution, propranolol, and steroids for thyroid storm...The clinical presentation can be variable and there is no clear laboratory cut‐off for serum TSH, T4, or T3, making the diagnosis a challenge. High suspicion is warranted, especially in patients with Grave's disease, for early diagnosis and prompt treatment of this life‐threatening condition.
  • ||||||||||  nipocalimab (M281) / J&J
    Trial primary completion date:  Vivacity-MG3: A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis (clinicaltrials.gov) -  Oct 26, 2022   
    P3,  N=190, Recruiting, 
    High suspicion is warranted, especially in patients with Grave's disease, for early diagnosis and prompt treatment of this life‐threatening condition. Trial primary completion date: Feb 2024 --> Nov 2023
  • ||||||||||  Journal:  Thomas Willis' legacy on the 400th anniversary of his birth. (Pubmed Central) -  Oct 25, 2022   
    He also described the striatum and cranial nerves. Furthermore, as a clinical neurologist, Willis participated in the description of various diseases, including myasthenia gravis and restless legs syndrome.
  • ||||||||||  methylprednisolone sodium succinate / Generic mfg.
    Journal:  Juvenile Generalized Myasthenia Gravis: Presented as Unilateral Blepharoptosis and Successfully Managed with Pulse Intravenous Methylprednisolone. (Pubmed Central) -  Oct 20, 2022   
    She did not respond to high dose (26 mg/kg/day) of Pyridostigmine and oral Prednisolone (2 mg/kg/day), but was successfully treated with a combination of pulse intravenous Methylprednisolone (30 mg/kg once a month for 6 months) and daily doses of oral Prednisolone (2 mg/kg/day) along with Pyridostigmine without significant side effects. This combination can be considered a potential inexpensive treatment for Juvenile Myasthenia Gravis in a resource limited area where other immunosuppressive treatments such as intravenous immunoglobulin is expensive and unaffordable.
  • ||||||||||  nerve & muscle (A 2–5) -  Oct 20, 2022 - Abstract #DGN2022DGN_115;    
    In this course we will present the current status of diagnostics, documentation of progress, established treatment options and the latest developments for acquired and hereditary polyneuropathies, myasthenic syndromes, and acquired and congenital myopathies. In addition to presenting the guideline content that will be new in 2022, we will summarize this and a selection of the latest results of the immunological and molecular clinical studies on the diseases.
  • ||||||||||  Journal:  Clinical characteristics and outcome predictors of a Chinese childhood-onset myasthenia gravis cohort. (Pubmed Central) -  Oct 18, 2022   
    Multivariate logistic regression analysis revealed that generalized myasthenia gravis type and positive status of antibodies against acetylcholine receptors were the independent risk factors for poor outcome. In conclusion, our childhood-onset myasthenia gravis patients present mainly as ocular myasthenia gravis, adequate immunotherapy improve the long-term outcome, and generalized myasthenia gravis phenotype as well as positive status of antibodies against acetylcholine receptors relate to poor outcome.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Journal:  Knowledge mapping of targeted immunotherapy for myasthenia gravis from 1998 to 2022: A bibliometric analysis. (Pubmed Central) -  Oct 18, 2022   
    In addition to "myasthenia gravis", the keyword with the highest consideration was "rituximab", followed by "double-blind", which indicate research hotspots gradually from basic research to clinical research over time, especially in the field of targeted immunotherapy...MG treatment has entered a personalized precision treatment phase. Further investigations into new target molecules and high-quality randomized controlled trials on existing biological agents are required urgently to direct future immunotherapy research.
  • ||||||||||  Rheumatological comorbidities and autoantibodies in NMOSD and MOGAD (ePoster Area) -  Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_904;    
    27 (18%) AQP4+ NMOSD patients had an autoimmune co-morbidity compared with 5 (9%) MOGAD patients. Diagnoses included, in the AQP4+ NMOSD group, 8 (5.3%) Sjogren’s, 7 (4.6%) systemic lupus erythematosus (SLE), 3 psoriasis, 3 autoimmune thyroid disease, 2 rheumatoid arthritis, 2 myasthenia gravis, 1 ulcerative colitis, and 1 immune thrombocytopenia.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Retrospective data, Journal:  Effects of rituximab on prognosis in myasthenia gravis: A single-center experience from Turkey (Pubmed Central) -  Oct 18, 2022   
    The improvement in MGFA-PIS scores post-RTX was similar in MuSK-Ab+ and AChR-Ab+ patients. The data are insufficient in seronegative and double seropositive patients and RTX must be considered in the treatment of suitable patients with MuSK-Ab+ and AChR-Ab+ refractory MG.